Search clinical trials for: Yttrium-90 carbon microspheres SIRT

Total 205 results

Zhongda Hospital

Recruiting

Yttrium-90 Carbon Microspheres in Patients With Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma

China
Chengdu New Radiomedicine Technology Co. LTD.

Recruiting

Safety and Efficacy of NRT6003 in Patients With Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma

China
Zhongda Hospital

Recruiting

Yttrium-90 Carbon Microspheres in Patients With Unresectable Colorectal Liver Metastases (NRT-uCRLM)

Unresectable Colorectal Liver Metastases

China
Thomas Jefferson University
National Cancer Institute (NCI); National Institutes of Health (NIH)

Active, not recruiting

Perflutren Protein-Type A Microspheres and Contrast-Enhanced Ultrasound in Improving Response to Radioembolization Therapy in Patients With Liver Cancer

Hepatocellular Carcinoma

United States
Emory University
National Cancer Institute (NCI); Sirtex Medical

Withdrawn

Radioembolization of Metastatic Breast Cancer to the Liver as a 2nd/3rd Line Therapy

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Breast Carcinoma | Metastatic Carcinoma in the Liver

United States
Sirtex Medical

Completed

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer (SIRFLOX)

Colorectal Cancer | Liver Metastases | Colorectal Carcinoma

United States, Israel, Australia, Belgium, New Zealand, Spain, Germany, Switzerland, Italy, France, Poland
GrandPharma (China) Co., Ltd.

Not yet recruiting

Observational Study for SIR-Spheres Therapy for the Treatment of Unresectable Metastatic Liver Tumors From Primary Colorectal Cancer

Colorectal Neoplasms

China
H. Lee Moffitt Cancer Center and Research Institute
BTG International Inc.

Completed

Study Of Intrahepatic Arterial Injection of 90-Y Glass Microspheres for Cholangiocarcinoma

Cholangiocarcinoma

United States
OHSU Knight Cancer Institute
Oregon Health and Science University; American Society of Clinical Oncology; Radiological... and other collaborators

Withdrawn

Y-90 Versus SBRT for Inoperable HCC

Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma AJCC v8 | Stage IB Hepatocellular Carcinoma AJCC v8 | Stage II Hepatocellular Carcinoma AJCC v8 | Stage... and other conditions

United States
Charite University, Berlin, Germany

Recruiting

Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis (SirTac)

Uveal Melanoma

Germany
University of Michigan Rogel Cancer Center
Department of Health and Human Services; National Institute for Biomedical...

Recruiting

Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy.

Liver Malignancy

United States
Seoul National University Hospital

Recruiting

Radiation Major Hepatectomy to Selectively Treat Large Unifocal Hepatocellular Carcinoma (RESCUE)

Hepatocellular Carcinoma

Korea, Republic of
M.D. Anderson Cancer Center
Sirtex Medical

Recruiting

Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases

Metastases

United States
Roger Williams Medical Center
Sirtex Medical

Completed

CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases (HITM-SIR)

Liver Metastases

United States
Boston Scientific Corporation

Suspended

First In Human Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device (VOYAGER)

Cancer | Prostate

United States
Methodist Health System

Recruiting

Evaluating the Effects of Selective Treatment Utilizing Flex-dosing for Unresectable HCC With Y90 SIR-Spheres

Hepatocellular Carcinoma

United States
Cardiovascular and Interventional Radiological...

Completed

CIRSE Registry for SIR-Spheres Therapy (CIRT)

Liver Carcinoma

Austria
Sirtex Medical
Bright Research Partners

Recruiting

Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients (DOORwaY90)

Unresectable Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | BCLC Stage A Hepatocellular Carcinoma

United States
Cardiovascular and Interventional Radiological...

Completed

CIRSE Registry for SIR-Spheres in France (CIRT-FR) (CIRT-FR)

Liver Cancer

France
Northwestern University
BTG International Inc.

Active, not recruiting

Yttrium-90 Radioembolization for Cirrhosis-Associated Thrombocytopenia

Thrombocytopenia | Cirrhosis

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Completed

Yttrium Y 90 Resin Microspheres Data Collection in Unresectable Liver Cancer: the RESIN Study (RESiN)

Localized Non-Resectable Adult Liver Carcinoma

United States
Tony Reid, M.D., Ph.D.
Sirtex Medical

Terminated

A Study of Yttrium-90 Radioactive Resin Microspheres to Treat Colorectal Adenocarcinoma Metastatic to the Liver

Liver Neoplasms | Colorectal Neoplasms

United States
Boston Scientific Corporation
BTG International Inc.

Completed

TheraSphere for the Treatment of Liver Metastases

Neoplasm Metastasis | Colorectal Cancer | Carcinoma, Neuroendocrine

United States
Northwestern University
National Cancer Institute (NCI)

Completed

Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Liver Cancer

United States
Allan Tsung

Withdrawn

Radiolabeled Glass Beads (TheraSphere®) in Treating Patients With Primary Liver Cancer That Cannot Be Removed by Surgery

Liver Cancer

United States
Wake Forest University Health Sciences

Completed

HDE Use Protocol of TheraSphere for Treatment of Unresectable HCC

Hepatocellular Carcinoma
Northwestern University
National Cancer Institute (NCI)

Completed

Radiolabeled Glass Beads in Treating Patients With Metastatic Liver Cancer That Cannot Be Removed by Surgery

Metastatic Cancer | Liver Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Yttrium Y 90 Glass Microspheres in Treating Patients With Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma...

United States
City of Hope Medical Center

No longer available

Yttrium Y 90 Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Liver Cancer

United States
Southwestern Regional Medical Center

Completed

Use of TheraSphere® Yttrium-90 Glass Microspheres for Primary and Metastatic Liver Tumors

Carcinoma, Hepatocellular | Liver Neoplasms

United States
University of Zurich

Withdrawn

Response of Hepatic Tumors to Radioembolization (RESRAD)

Hepatocellular Carcinoma | Intrahepatic Cholangiocarcinoma | Liver Metastasis

Switzerland
University of California, San Francisco
Taiho Pharmaceutical Co., Ltd.; Sirtex Medical

Completed

Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases

Rectal Cancer | Colon Cancer | Liver Metastases

United States
Leo W. Jenkins Cancer Center

No longer available

Therasphere® for Treatment of Unresectable Primary Liver Cancer and Metastatic Liver Cancer

Neoplasm Metastasis | Carcinoma, Hepatocellular

United States
Boston Scientific Corporation
Biocompatibles UK Ltd

Active, not recruiting

Non-Interventional Registry Study to Evaluate the Effectiveness of TheraSphere® in the Treatment of Hepatocellular Carcinoma (HCC) (PROACTIF)

Hepatocellular Carcinoma

France
Yale University

Completed

Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors

Liver Neoplasms

United States
Nicholas Fidelman, MD
Merck Sharp & Dohme LLC; BTG International Inc.

Active, not recruiting

Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases

Neuroendocrine Neoplasm | Metastatic Malignant Neoplasm in the Liver

United States
University of Southern California
National Cancer Institute (NCI)

Withdrawn

Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing Yttrium-90 Radioembolization

Hepatocellular Carcinoma

United States
Chinese University of Hong Kong

Completed

Treatment for Bile Duct Cancer in the Liver

Cholangio Carcinoma

Hong Kong
M.D. Anderson Cancer Center
Sirtex Medical

Withdrawn

Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Mets to Liver

Colorectal Cancer | Colon Cancer
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

Internal Radiation Therapy in Treating Patients With Primary Liver Cancer That Cannot Be Removed by Surgery

Liver Cancer

United States
Goshen Health System

Unknown

Internal Radiation Therapy With Y-90 Microspheres, External Radiation Therapy With Tomotherapy, and Fluorouracil in Treating Patients With Newly Diagnosed or Recurrent Pancreatic Cancer and Liver Metastases That Cannot Be Removed By Surgery

Pancreatic Cancer | Metastatic Cancer

United States
University of Pittsburgh
National Cancer Institute (NCI)

Completed

Hepatic Arterial Chemoembolization With Cisplatin or Internal Radiation Therapy in Treating Patients With Advanced Liver Cancer That Cannot Be Removed By Surgery

Liver Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D)

Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma...

United States
Ohio State University Comprehensive Cancer Center

Completed

Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma

United States
Singapore Clinical Research Institute
National Medical Research Council (NMRC), Singapore; Sirtex Medical; Bayer Healthcare...

Completed

Study of SIR-Spheres Plus Sorafenib as 1st Line Treatment for Non-resectable Primary Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma

Singapore, Korea, Republic of, Malaysia, Myanmar
Fondazione IRCCS Istituto Nazionale dei Tumori,...
Gastro Intestinal Surgery and Liver Transplantation; The Hepato-Oncology Group...

Completed

Radioembolization With Yttrium-90 Microspheres for Intermediate or Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma | Liver Cancer

Italy
University of California, San Francisco

Terminated

Yttrium-90 Radioembolization With Glass Microspheres (TheraSphere) for Patients With Hepatocellular Carcinoma

Hepatocellular Carcinoma

United States
OHSU Knight Cancer Institute
Oregon Health and Science University; Boston Scientific Corporation

Completed

Radiolabeled Glass Beads Used for Treating Patients With Primary Liver Cancer When Surgery is Not an Option (Y-90HDE)

Liver Cancer | Hepatoma
Singapore General Hospital
National Cancer Centre, Singapore; National Medical Research Council (NMRC)... and other collaborators

Unknown

Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (HCC) (SIRveNIB)

Hepatocellular Carcinoma

Taiwan, Korea, Republic of, Malaysia, New Zealand, Philippines, Singapore, China, Thailand, Brunei Darussalam, Indonesia, Mongolia, Myanmar
Zhongda Hospital

Recruiting

Efficacy and Safety of 90Y Microsphere Combined With FOLFIRI and Bevacizumab in Second-line Treatment of CRLM

Colorectal Cancer Metastatic

China

Search clinical trials for: Yttrium-90 carbon microspheres SIRT

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Taiwan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations